Hepatitis a-g prevention, diagnosis, and therapy

Comprehensive Therapy

Volumn 23, Issue 7, 1997, Pages 482-490

  Levinson, Michael J ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b 80 Humphries Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; INTERFERON; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

CLINICAL TRIAL; DELTA AGENT HEPATITIS; DEPRESSION; FATIGUE; FLU LIKE SYNDROME; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; REVIEW; VIRUS HEPATITIS;

HEPATITIS VIRUSES; HEPATITIS, VIRAL, HUMAN; HUMANS;

EID: 0030841347     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Lemon SM. Type a viral hepatitis: new developments in an old disease. N Engl J Med. 1985; 313:1059-1067.
2. Gordon SC, Reddy KR, Schiff I, et al. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med. 1984; 101:635-637.
3. Wilner JR, Williams EQ, Uhl SG, et al. Clinical features of severe hepatitis A in an urban epidemic. Hepatology. 1996: 410A. Abstract 1136.
4. Glickson M, Galun E, Oren R, et al. Relapsing hepatitis A: review of 14 cases. Medicine. 1992; 71:14-23.
5. Centers for Disease Control and Prevention. Protection against viral hepatitis: recommendations of the immunization practices advisory committee. MMWR. 1990; 39:S-Z.
6. Leentvaar-Kuijpers A, Continho RA, Brulein V, et al. Simultaneous passive and active immunization against hepatitis A. Vaccine. 1992; 10(suppl):138-141.
7. Andre FE. Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine. Vaccine. 1992; 10(suppl 1):S160-S168.
8. Westbom TU, Gudipati S, Derousse C, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine effect of dose and vaccination schedule. J Infect Dis. 1994; 1:69:996-1001.
9. Yoffe B, Noonan CA. Hepatitis B virus: new and evolving issues. Dig Dis. 1992:37:1-9.
10. Chau KH, Margie MP, Decker RH. Evaluation of serodiagnosis of recent hepatitis B infection by IgM class Anti-HBC. Hepatology. 1983; 3:142-149.
11. Norkran SG, Hermodsson S, Lundin P. Evaluation of long term outcome of hepatitis B. Infection. 1976; 4:17-72.
12. Alward WLM, McMahon BJ, Hall DB, et al. The long-term serological course of asymptomatic hepatitis B virus carries. J Infect Dis. 1985; 141: 604-609.
13. De Franchis R, Mencci G, Vecchi M, et al. Natural history of an asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 1993; 118:191-194,
14. Wu J-C, Chen C-M, Chen T-Z, et al. Prevalence and type precore hepatitis B mutants. J Infect Dis. 1996; 173:457-459.
15. Carmen W, Pagan E, Hadziyanna S, et al. Vaccine induced escape mutant of hepatitis B virus. Lancet. 1990; 336:325-329.
16. Mojardino J, Velosa J, Thomas SHC, et al. Serum HBV DNA: HBV carriers and patients with acute liver disease. J Hepatol. 1991; 13:44.
17. Centers for Disease Control and Prevention. Hepatitis B virus: comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 1991; 49:rr 13.
18. Wood AJ. Vaccines to prevent viral hepatitis. N Engl J Med. 1997; 336:196.
19. Chinn J. Effects of mass hepatitis B vaccine among children. JAMA. 1996; 276:906.
20. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine. JAMA. 1987; 257:2612-2616.
21. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis vaccine. N Engl J Med. 1989:321:708-712.
22. Hourvitz A, Mosseri R, Solomon A, et al. Reactogenecity and immunogenicity of a new recombinant hepatitis B vaccine containing pre s antigen. J Viral Hepatitis. 1996: 3:337-342.
23. Perrillo RP, Schiffer D, Davis GL, et al. A randomized controlled trial of interferon alfa-2B alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N EngI J Med., 1990:323:295-301.
24. Hoofnagle JH, Dibisceolie AM, Waggoner JG, et al. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology. 1993:104:1116-1121.
25. Denstag IL, Perillo RP, Schiffer J, et al A preliminary trial of lamivudine for chronic hepatitis B. N Eng J Med 1995:333:1657-1661.
26. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis B virus resistant to lamivudine given for recurrent infection after OLT. Lancet. 1997: 349:20-23.
27. Choo QL, Ku DG, Weiner AL, et al. Isolation of a C DNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244:359-361.
28. McHutchhison JG, Person JL, Govindarajan S, et al. Improved detection of hepatitis C virus antibodies in high risk populations, Hepatology. 1992:15:1-25.
29. Sjögren MH. Serologic diagnosis of viral hepatitis. Med Clinics NA. 1996:80;941-948.
30. Sauerbruch, et al. Hepatitis C silent epidemic. J Hepatology. 1996; 24(suppl 2).
31. Vander Poel CL, Cuypers HT, Reesink HW. Hepatitis C virus: six years on. Lancet. 1994: 344:1475-1479.
32. Hallam NF, Fletcher ML, Read SJ, et al. Low risk of sexual transmission of hepatitis C virus. J Med Virology. 1993:40:251-253.
33. Koretz R, King P. Chronic viral hepatitis and use of interferon. Postgrad Med. 1996; 100:55-78.
34. Dusheiko GM, Khaoo S, Soni P, et al. A rational approach to the management of hepatitis C infection. BMJ 1996; 312(7027):357-364.
35. Booth JC, Brown JL, Thomas HC. The management of chronic hepatitis C. Gut. 1995:37:449-454.
36. Ampurdanes S, Olmedo E, Maleunda M, et al. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum. J Hepatology. 1996; 25:327-332.
37. Davis G, Baiart I, Schiff E, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med. 1989; 321:1501-1506.
38. Ming-Yang LAI, Jia Horng KAO, Pet-Ming Yang, et al. Long-term efficacy of ribavirin plus Interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 1996; 111:1307-1312.
39. Rizello M. The delta agent, Hepatology. 1983; 5: 729-737.
40. De Cock KM, Govindarajans S, Chin K, et al. Delta hepatitis in the Los Angeles area: report of 126 cases. Ann Intern Med. 1986; 105:108-114.
41. Aragona M, Macagno S, Canedda F, et al, Serological response to hepatitis delta virus in hepatitis D. Lancet. 1987; XX:478-480.
42. Alter MJ. Delta hepatitis and infection in North America. In: Alter MJ, ed. Hepatitis Delta Virus Molecular Biology: Pathogenesis and Clinical Aspects. New York, NY; Wiley-Liss. 1993: 243-250.
43. Fare P, Mandas A, Coiana A, et al. Treatment of chronic delta hepatitis D with interferon alfa-2a. N Engl J Med. 1994; 330:88-94.
44. Bryamn JP, Tsarev SA, Igbul M, et al. Epidemic hepatitis E in Pakistan: patterns of serology response and evidence that antibody to hepatitis E virus protects against disease. J Infect Dis. 1994; 170:517-521.
45. Klauroo MS, Rustgi VK, Dawson GL, et al. Spectrum of hepatitis E virus infection. J Med Virology. 1994; 43:281-286.
46. Krawczynski K. Hepatitis E. Hepatology. 1993; 17:932-941.
47. Linnen JN, Lary TP, Dawson FG, et al. Isolation of a novel virus-like sequence associated with human hepatitis. Nat Med. 1995; 1:564-569.
48. Leary TP, Muerhoff AS, Simons JW. EVAL sequence and genomic organization of HBV-C: a novel member of the flavivirdue associated human non-A-E hepatitis. J Med Virol. 1996; 48:60-67.
49. Linnen J, Wages T, Azhang-Keckz A, et al. Molecular cloning and disease associated with hepatitis G, A transfusion-transmissible agent. Science. 1996; 271:505-508.
50. Masuko K, Mitsui T, Iwano K, et al. GV-C1 disease in hemodialysis patients. N Engl J Med. 1996; 334:1485-1490.
51. Btalet M-P, Rondot T, Pawlotsky J, et al. Histopathologic impact of HB virus C infection, impact of HB virus, impact of GB virus C infection on chronic hepatitis C. Gastroenterology. 1997; 112:118-193.
52. Pawlosky JM, Thorval F, Pelerrin A, et al. GBV-C infection in HCV infected patients: response to interferon. Hepatology. 1996: AbG 397;226 A.